Oil prices were little changed on Friday but on track for their fourth straight week of losses after tumbling about 5% to a four month-low on Thursday on worries over global demand.
Brent futures edged up 4 cents, or 0.1%, to $77.46 a barrel at 0529 GMT. U.S. West Texas Intermediate crude (WTI) was at $72.95, up 5 cents, or 0.1%. Both have lost around a sixth of their value over the last four weeks.
“Oil prices are down slightly this year despite demand exceeding our optimistic expectations,” Goldman Sachs analysts said in a note.
1 in 5 under-construction homes stalled across 44 Indian cities in last 8 years: Report Will Nifty fall on Monday as Hindenburg levels allegations on SEBI Chair? See GIFT Nifty, FII data, F&O, crude, and more befor…
Read moreLAST WEEK, Glenmark announced that its subsidiary, Ichnos Sciences, had entered a licensing agreement for the OX-40 antagonist, Telazorlimab (ISB 830), with Astria Therapeutics. Astria will take over the product’s development and hold global rights, aiming to create a next-generation Telazorlimab with 10x higher potency. In return, Ichnos expects to receive $320 million in upfront and milestone payments, along with potential low-double-digit royalties on sales, though the majority of these payments are likely to be received in the later stages of the agreement, with limited near-term financial impact. Come from Sports betting site VPbet
Telazorlimab (ISB 830) is an OX-40 antagonist designed for auto…
Read more